Thromb Haemost 2004; 92(06): 1229-1231
DOI: 10.1055/s-0037-1614301
DOI: 10.1055/s-0037-1614301
Theme Issue Letter to the Editor
Combined coagulation phase-directed factor Xa inhibition with heparin compounds and DX-9065a - A direct and selective antagonist
Authors
-
Richard C. Becker
1 Cardiovascular Thrombosis Center, Duke University Medical Center, Durham, North Carolina, USA2 Duke Clinical Research Institute Durham, North Carolina, USA -
John Alexander
1 Cardiovascular Thrombosis Center, Duke University Medical Center, Durham, North Carolina, USA2 Duke Clinical Research Institute Durham, North Carolina, USA -
You Fu Li
3 Laboratory for Vascular Biology Research, UMASS Memorial Medical Center,Worcester, Massachusetts, USA -
Edwin Bovill
4 Department of Pathology, University of Vermont, Burlington, Vermont, USA -
Frederick A. Spencer
3 Laboratory for Vascular Biology Research, UMASS Memorial Medical Center,Worcester, Massachusetts, USA -
Thomas L. Robertson
5 Daiichi Pharmaceuticals, Inc.,Tokyo, Japan -
Satoshi Kunitada
5 Daiichi Pharmaceuticals, Inc.,Tokyo, Japan -
Christopher K. Dyke
1 Cardiovascular Thrombosis Center, Duke University Medical Center, Durham, North Carolina, USA2 Duke Clinical Research Institute Durham, North Carolina, USA -
Robert A. Harrington
1 Cardiovascular Thrombosis Center, Duke University Medical Center, Durham, North Carolina, USA2 Duke Clinical Research Institute Durham, North Carolina, USA